We undertook a 26 week, multicentre, open-label, random-ised, parallel-group study at 105 sites in 19 countries (Argentina, Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Hungary, Israel, Italy, Mexico, Poland, Romania, Slovakia, South Africa, South Korea, Spain, and Taiwan) between Jan 11, 2010, and Jan 17, 2011. Eligible patients had type 2 diabetes, were at least  18 years of age, and had suboptimum glycaemic control despite lifestyle modiﬁ  cation (diet and exercise) and  maximum or near maximum dose of oral antihyper-glycaemic drugs (metformin, sulfonylurea, metformin plus sulfonylurea, or metformin plus pioglitazone). Inclusion criteria were a HbA 1c concentration between  7·1% and 11·0% (54 mmol/mol to 97 mmol/mol), inclusive; a body-mass index of 45 kg/m² and less; and a stable bodyweight for at least 3 months. Exclusion criteria were active cardiac disease within 3 months of screening; inﬂ ammatory bowel disease or other severe gastro-